Navigation Links
Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting
Date:5/30/2009

SEATTLE, WA, May 30 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) (the "Company") today announced that data from clinical trials for three of the Company's product candidates were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting on May 30, 2009 in Orlando, Florida. The presentations included long-term safety data from the Phase 2b trial of Stimuvax(R) in patients with stage IIIB/IV non-small cell lung cancer, preliminary results from the Phase 1 trial of the phosphoinositide-3-kinase (PI-3 kinase) inhibitor PX-866 in patients with advanced malignancy, and final results from two Phase 1b trials of the thioredoxin inhibitor PX-12 in advanced cancer patients.

Stimuvax

Data concerning the long-term safety of Stimuvax (BLP25 liposomal vaccine) were presented by Dr. Charles Butts, Cross Cancer Institute, Edmonton, Alberta. Sixteen patients who received Stimuvax for between 2 and 8.2 years as part of the Phase 2b trial in patients with stage IIIb/IV non-small cell lung cancer (NSCLC) were studied. Ten of these patients have been treated for more than five years, and eight continue to receive therapy with Stimuvax. Prolonged treatment with Stimuvax was well-tolerated in this trial. The most common treatment-related adverse events were injection site reactions, which tended to diminish after the first year of treatment. There was no evidence of autoimmune reactions with prolonged use.

"We are very pleased that this group of long-term survivors with advanced NSCLC has been able to continue to receive Stimuvax with apparent safety for up to eight years," said Robert L. Kirkman, M.D., President and Chief Executive Officer of Oncothyreon. "These patients were treated as part of the randomized Phase 2b trial conducted by Oncothyreon, in which the subset of patients with Stage IIIb locoregi
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Biomira announces plan to change name to Oncothyreon
2. Oncothyreon highlights corporate and clinical objectives for 2008
3. Oncothyreon to present at BIO CEO & Investor Conference
4. Oncothyreon launches new corporate website
5. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
6. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
7. Oncothyreon reports full year and fourth quarter 2007 financial results
8. Oncothyreon to present at upcoming investment conferences
9. Oncothyreon announces issuance of patent for PX-867
10. Oncothyreon announces effectiveness of shelf registration statement
11. Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Cayenne Medical, Inc., a privately held ... tissue reconstruction segment, announced the worldwide launch of ... the shoulder and extremities. The SureLock System provides ... method. The unique delivery eliminates manual tensioning that ... anchor displacement (also commonly know as anchor “creep”). ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Deep ... Century Medicine Forum on ‘Commercialising Longevity Research’ and ... entrepreneurs to the London Bioscience Innovation Center for ... Foundation and Aging Analytics Ltd. The meeting highlighted ... in translational research for age-related disease, as well ...
(Date:7/10/2014)... Francisco, CA (PRWEB) July 10, 2014 ... family closer together. The Archer Family purchased a ... contained within DNA, but ended up with a lifetime ... discoveries contained within the family members’ DNA genuinely brought ... had decided to search deeper into genetic history and ...
(Date:7/10/2014)... EvoDerma ’s NOOME Anti-Aging Motion has ... now comes with a second treatment cup to help prevent ... new cup is thinner on the edges for a softer ... thin and uneven surfaces on the face, neck and décolleté. ... treatment on areas such as the cheeks and neck, or ...
Breaking Biology Technology:Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2
... 23, 2010Scientists at the Gladstone Institute of Neurological Disease ... in Alzheimer,s disease (AD) and other neurodegenerative diseases. The ... "We examined a protein called tau that ... Gan, PhD, senior author on the study. "Tau forms ...
... LONDON and SAN FRANCISCO, September 22, 2010 ... ... ... Results are keyed by longUrl, so we need to grab the first one. for (var r in ...
... SINGAPORE, Sept. 23 S*BIO Pte Ltd today ... that will support the continued development of S*BIO,s ... commitment reflects the international investment community,s strong interest ... through clinical development and the quality of our ...
Cached Biology Technology:Gladstone scientists identify strategy to reduce toxic proteins associated with Alzheimer's disease 2Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients 2Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients 3Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients 4Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients 5Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients 6Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients 7Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients 8Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients 9Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients 10S*BIO Announces US$5 Million Investment by Mitsui Ventures 2S*BIO Announces US$5 Million Investment by Mitsui Ventures 3
(Date:7/11/2014)... new report from the Wildlife Conservation Society shows ... help economically valuable species such as lobster, conch, ... help re-colonize nearby reef areas. , The reporttitled ... systematic review of research literature from no-take areas ... Dr. Craig Dahlgren, a recognized expert in marine ...
(Date:7/11/2014)... new professorship in tissue engineering to promote innovative ... and the Marine Biological Laboratory, supported by a ... Bell Foundation., The Eugene Bell Professorship in Tissue ... Engineering. That endowed chair holder also will direct ... Center for Regenerative Biology and Tissue Engineering, and ...
(Date:7/11/2014)... Shenzhen, China Researchers from Salk Institute for Biological ... time evaluated the safety and reliability of the ... a new method, TALEN-HDAdV, which could significantly increased ... (hiPSC). This study published online in Cell ... for stem cell-based gene therapy. , The combination ...
Breaking Biology News(10 mins):Belize's lobster, conch, and fish populations rebuild in no-take zones 2New professorship in tissue engineering links molecular engineering, marine biology 2A new genome editing method brings the possibility of gene therapies closer to reality 2
... a common goal: making the invisible visible. Yet artistically ... careers. A new four-year, $1.2 million program led by ... and physics of color into a series of summer ... art-interested students to enter careers in science. , ...
... be heading into the rainforests of Nicaragua to help an endangered ... crops are being threatened by the animals. The animals were ... just two years ago when the MSU team discovered them still ... up of still and video cameras in order to "capture" the ...
... New Rochelle, NY, November 15, 2012Epstein-Barr virus (EBV) is ... serious disease in liver transplant recipients. Molecular tests that ... have value for diagnosing active infection. The benefits of ... EBV-infected transplant patients are evaluated in an article published ...
Cached Biology News:New programs draws young artists into science 2Collaring tapirs to help them survive 2
... is one of several isoprostanes produced from arachidonic ... renal vasoconstrictor in the rat. 8-iso PGE2 inhibits ... of 0.5 and 5 µM, respectively. When infused ... a concentration of 4 mg/kg/min, 8-iso PGE2 decreases ...
DNA Polymerase I Large (Klenow) Fragment is a DNA polymerase that lacks the 5'Cut Site3' exodeoxyribonuclease activity of intact DNA Polymerase I but it contains the 3'Cut Site5' exodeoxyribonuclease...
... offers both high-speed and high-volume versatility ... rotor options, making it ideal for a ... Versatility , High-speed (up to 15,000 ... high-volume (4 x 250mL) swinging bucket rotors ...
Guanylate Kinase Purified Anti-Mouse, Anti-Rat clone 28, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
Biology Products: